feed,title,long_url,short_url
SeekingAlpha,"Jazz Pharma, Zymeworks announce 84% overall survival at 18 months from phase 2 trial testing Zanidatamab",https://seekingalpha.com/news/3925943,
SeekingAlpha,"Jazz Pharma, Zymeworks post 84% overall survival for GIT cancer candidate",https://seekingalpha.com/news/3925942,
SeekingAlpha,Alcoa slips as Q4 EBITDA miss prompts concern over lower aluminum prices,https://seekingalpha.com/news/3925941,
SeekingAlpha,Microsoft: Disruption Is Unforgiving If You Fall Behind,https://seekingalpha.com/article/4570901,
